MYRIAD GENETICS, INC. Excess Tax Benefit from Share-based Compensation, Operating Activities
MYRIAD GENETICS, INC. (MYGN) reported Excess Tax Benefit from Share-based Compensation, Operating Activities of $17.90 million for the 9-month period ending 2016-03-31, per its 10-Q filed 2016-05-04.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities · last filed 2017-08-09
- MYRIAD GENETICS, INC. excess tax benefit from share-based compensation, operating activities for the quarter ending 2016-03-31 was $1.80M, a 200.00% increase year-over-year.
- MYRIAD GENETICS, INC. excess tax benefit from share-based compensation, operating activities for the quarter ending 2015-12-31 was $11.20M, a 1144.44% increase year-over-year.
- MYRIAD GENETICS, INC. excess tax benefit from share-based compensation, operating activities for the quarter ending 2015-09-30 was $4.90M, a 188.24% increase year-over-year.
- MYRIAD GENETICS, INC. excess tax benefit from share-based compensation, operating activities for the quarter ending 2015-06-30 was $200.00K, a 96.66% decline year-over-year.
- MYRIAD GENETICS, INC. excess tax benefit from share-based compensation, operating activities for fiscal 2015 was $3.40M, a 69.37% decline from fiscal 2014.
- MYRIAD GENETICS, INC. excess tax benefit from share-based compensation, operating activities for fiscal 2014 was $11.10M, a 40.51% increase from fiscal 2013.
- MYRIAD GENETICS, INC. excess tax benefit from share-based compensation, operating activities for fiscal 2013 was $7.90M, a 76.90% decline from fiscal 2012.
- MYRIAD GENETICS, INC. excess tax benefit from share-based compensation, operating activities for fiscal 2012 was $34.19M, a 41.88% decline from fiscal 2011.
| Period end | Excess Tax Benefit from Share-based Compensation, Operating Activities 3 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 3 month as first filed | Excess Tax Benefit from Share-based Compensation, Operating Activities 6 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 6 month as first filed | Excess Tax Benefit from Share-based Compensation, Operating Activities 9 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 9 month as first filed | Excess Tax Benefit from Share-based Compensation, Operating Activities 12 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2016-03-31 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-04 | $13.00M derived: sum of 2 quarters · filed 2016-05-04 | $17.90M 10-Q · filed 2016-05-04 | $18.10M derived: sum of 4 quarters · filed 2017-08-09 | ||||
| 2015-12-31 | $11.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-03 | $16.10M 10-Q · filed 2016-02-03 | $16.30M derived: sum of 3 quarters · filed 2017-08-09 | $16.90M derived: sum of 4 quarters · filed 2017-08-09 | ||||
| 2015-09-30 | $4.90M 10-Q · filed 2015-11-04 | $5.10M derived: sum of 2 quarters · filed 2017-08-09 | $5.70M derived: sum of 3 quarters · filed 2017-08-09 | $6.60M derived: sum of 4 quarters · filed 2017-08-09 | ||||
| 2015-06-30 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-09 | $800.00K derived: sum of 2 quarters · filed 2017-08-09 | $1.70M derived: sum of 3 quarters · filed 2017-08-09 | $3.40M 10-K · filed 2017-08-09 | ||||
| 2015-03-31 | $600.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-04 | $1.50M derived: sum of 2 quarters · filed 2016-05-04 | $3.20M 10-Q · filed 2016-05-04 | $3.20M 10-Q · filed 2015-05-06 | $9.19M derived: sum of 4 quarters · filed 2016-08-10 | |||
| 2014-12-31 | $900.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-03 | $2.60M 10-Q · filed 2016-02-03 | $2.63M 10-Q · filed 2015-02-04 | $8.59M derived: sum of 3 quarters · filed 2016-08-10 | $13.11M derived: sum of 4 quarters · filed 2016-08-10 | |||
| 2014-09-30 | $1.70M 10-Q · filed 2015-11-04 | $1.68M 10-Q · filed 2014-11-05 | $7.69M derived: sum of 2 quarters · filed 2016-08-10 | $12.21M derived: sum of 3 quarters · filed 2016-08-10 | $12.79M derived: sum of 4 quarters · filed 2016-08-10 | |||
| 2014-06-30 | $5.99M derived: 10-K 12 month − 10-Q 9 month · filed 2016-08-10 | $10.51M derived: sum of 2 quarters · filed 2016-08-10 | $11.09M derived: sum of 3 quarters · filed 2016-08-10 | $11.10M 10-K · filed 2016-08-10 | $11.14M 10-K · filed 2014-08-13 | |||
| 2014-03-31 | $4.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-06 | $5.09M derived: sum of 2 quarters · filed 2015-05-06 | $5.11M 10-Q · filed 2015-05-06 | $7.74M derived: sum of 4 quarters · filed 2015-08-12 | ||||
| 2013-12-31 | $578.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-04 | $592.00K 10-Q · filed 2015-02-04 | $3.23M derived: sum of 3 quarters · filed 2015-08-12 | $4.87M derived: sum of 4 quarters · filed 2015-08-12 | ||||
| 2013-09-30 | $14.00K 10-Q · filed 2014-11-05 | $2.65M derived: sum of 2 quarters · filed 2015-08-12 | $4.29M derived: sum of 3 quarters · filed 2015-08-12 | $7.45M derived: sum of 4 quarters · filed 2015-08-12 | ||||
| 2013-06-30 | $2.63M derived: 10-K 12 month − 10-Q 9 month · filed 2015-08-12 | $4.28M derived: sum of 2 quarters · filed 2015-08-12 | $7.44M derived: sum of 3 quarters · filed 2015-08-12 | $7.90M 10-K · filed 2015-08-12 | $7.89M 10-K · filed 2013-08-14 | |||
| 2013-03-31 | $1.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-07 | $4.80M derived: sum of 2 quarters · filed 2014-05-07 | $5.26M 10-Q · filed 2014-05-07 | $7.26M derived: sum of 4 quarters · filed 2014-08-13 | ||||
| 2012-12-31 | $3.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-02-05 | $3.62M 10-Q · filed 2014-02-05 | $5.62M derived: sum of 3 quarters · filed 2014-08-13 | $6.33M derived: sum of 4 quarters · filed 2014-08-13 | ||||
| 2012-09-30 | $463.00K 10-Q · filed 2013-11-12 | $2.46M derived: sum of 2 quarters · filed 2014-08-13 | $3.17M derived: sum of 3 quarters · filed 2014-08-13 | $17.62M derived: sum of 4 quarters · filed 2014-08-13 | ||||
| 2012-06-30 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-13 | $2.70M derived: sum of 2 quarters · filed 2014-08-13 | $17.15M derived: sum of 3 quarters · filed 2014-08-13 | $34.19M 10-K · filed 2014-08-13 | ||||
| 2012-03-31 | $708.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-05-08 | $15.16M derived: sum of 2 quarters · filed 2013-05-08 | $32.20M 10-Q · filed 2013-05-08 | $46.85M derived: sum of 4 quarters · filed 2013-08-14 | ||||
| 2011-12-31 | $14.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-02-06 | $31.49M 10-Q · filed 2013-02-06 | $46.14M derived: sum of 3 quarters · filed 2013-08-14 | $62.63M derived: sum of 4 quarters · filed 2013-08-14 | ||||
| 2011-09-30 | $17.04M 10-Q · filed 2012-11-09 | $31.69M derived: sum of 2 quarters · filed 2013-08-14 | $48.18M derived: sum of 3 quarters · filed 2013-08-14 | $63.51M derived: sum of 4 quarters · filed 2013-08-14 | ||||
| 2011-06-30 | $14.65M derived: 10-K 12 month − 10-Q 9 month · filed 2013-08-14 | $31.14M derived: sum of 2 quarters · filed 2013-08-14 | $46.47M derived: sum of 3 quarters · filed 2013-08-14 | $58.83M 10-K · filed 2013-08-14 | -$58.83M 10-K · filed 2011-08-15 | |||
| 2011-03-31 | $16.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-05-02 | $31.82M derived: sum of 2 quarters · filed 2012-05-02 | $44.18M 10-Q · filed 2012-05-02 | |||||
| 2010-12-31 | $15.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-02-01 | $27.69M 10-Q · filed 2012-02-01 | ||||||
| 2010-09-30 | $12.36M 10-Q · filed 2011-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |